Financial giants have made a conspicuous bearish move on Vertex Pharmaceuticals ... Money on the Move Benzinga Edge's Unusual Options board spots potential market movers before they happen.

Life Science Washington, the state’s life sciences industry association, announced the expansion of its board of directors with the ad ...

Financial giants have made a conspicuous bearish move on Vertex Pharmaceuticals ... Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions ...

Vertex Pharmaceuticals Incorporated (Nasdaq ... Nelnet, Inc. today announced the Nelnet Board of Directors declared a first quarter cash dividend on the company's outstanding shares of Class A common ...

The FDA has approved a new type of painkiller that doesn't come with the risks of addiction and overdose associated with ...

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval ... FDA Center for Drug Evaluation and Research Acting Director Dr. Jacqueline Corrigan-Curay said.

A novel Vertex Pharmaceuticals drug that takes a new ... in acute pain management,” Jacqueline Corrigan-Curay, acting director of the FDA’s Center for Drug Evaluation and Research, said ...

The Food and Drug Administration approved Vertex Pharmaceuticals' non-opioid painkiller ... said Dr. Jacqueline Corrigan-Curay, acting director of the FDA's Center for Drug Evaluation and Research ...

The movement to steer pain treatment away from opioids notched a major victory Thursday, as the Food and Drug Administration approved a new, highly anticipated drug from Vertex Pharmaceuticals ...

The medication will be sold under the brand name Journavx for $15.50 per pill, according to Vertex Pharmaceuticals ... Jacqueline Corrigan-Curay, acting director of the FDA’s Center for ...

To put it mildly, last Tuesday was a “stressful day” for state Medicaid staff across the country, a former Medicaid director ... to cover Vertex’s pain drug Vertex Pharmaceuticals received ...